CA2343602A1 - Est et proteines humaines codees - Google Patents
Est et proteines humaines codees Download PDFInfo
- Publication number
- CA2343602A1 CA2343602A1 CA002343602A CA2343602A CA2343602A1 CA 2343602 A1 CA2343602 A1 CA 2343602A1 CA 002343602 A CA002343602 A CA 002343602A CA 2343602 A CA2343602 A CA 2343602A CA 2343602 A1 CA2343602 A1 CA 2343602A1
- Authority
- CA
- Canada
- Prior art keywords
- nos
- seq
- sequences
- sequence
- est
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Landscapes
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19787300P | 2000-04-18 | 2000-04-18 | |
US60/197,873 | 2000-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2343602A1 true CA2343602A1 (fr) | 2001-10-18 |
Family
ID=22731080
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002343602A Abandoned CA2343602A1 (fr) | 2000-04-18 | 2001-04-17 | Est et proteines humaines codees |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2343602A1 (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7365154B2 (en) * | 2003-06-23 | 2008-04-29 | Centocor, Inc. | Peptides antagonistic to an anti-angiogenic antibody and uses therefor |
US7713521B2 (en) | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
US9388215B2 (en) | 2013-03-15 | 2016-07-12 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
WO2017173321A1 (fr) * | 2016-03-31 | 2017-10-05 | Neon Therapeutics, Inc. | Néoantigènes et leurs procédés d'utilisation |
WO2017182395A1 (fr) * | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunothérapie contre le mélanome et d'autres cancers |
CN110064045A (zh) * | 2019-05-15 | 2019-07-30 | 苏州大学 | 微肽cip2a-bp在治疗癌症中的应用 |
US10435455B1 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
AU2021244056B2 (en) * | 2020-03-27 | 2024-04-04 | Onecuregen Co., Ltd. | Composition comprising VGLL1 peptide for treatment of cancer |
WO2024165674A1 (fr) * | 2023-02-08 | 2024-08-15 | Guard Therapeutics International AB | Fragments peptidiques dérivés de alpha-1-microglobuline et leurs utilisations |
-
2001
- 2001-04-17 CA CA002343602A patent/CA2343602A1/fr not_active Abandoned
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7365154B2 (en) * | 2003-06-23 | 2008-04-29 | Centocor, Inc. | Peptides antagonistic to an anti-angiogenic antibody and uses therefor |
US7713521B2 (en) | 2005-08-12 | 2010-05-11 | Schering Corporation | MCP1 fusions |
US7972591B2 (en) | 2005-08-12 | 2011-07-05 | Schering Corporation | Methods for treating rheumatoid arthritis and multiple sclerosis using MCP1 fusions |
US8282914B2 (en) | 2005-08-12 | 2012-10-09 | Merck, Sharp & Dohme Corp. | Method for treating atherosclerosis by administering human MCP1 fusions |
US8614311B2 (en) | 2007-12-12 | 2013-12-24 | Quark Pharmaceuticals, Inc. | RTP801L siRNA compounds and methods of use thereof |
US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
US9758807B2 (en) | 2012-12-05 | 2017-09-12 | SOLA Biosciences, LLC | Protein expression enhancing polypeptides |
AU2013355120B2 (en) * | 2012-12-05 | 2017-11-09 | Sola Biosciences Llc | Protein expression enhancing polypeptides |
US9388215B2 (en) | 2013-03-15 | 2016-07-12 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
US9738695B2 (en) | 2013-03-15 | 2017-08-22 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
US10899815B2 (en) | 2013-03-15 | 2021-01-26 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
WO2017173321A1 (fr) * | 2016-03-31 | 2017-10-05 | Neon Therapeutics, Inc. | Néoantigènes et leurs procédés d'utilisation |
US10519216B2 (en) | 2016-04-21 | 2019-12-31 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US10435455B1 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
WO2017182395A1 (fr) * | 2016-04-21 | 2017-10-26 | Immatics Biotechnologies Gmbh | Immunothérapie contre le mélanome et d'autres cancers |
US10364281B2 (en) | 2016-04-21 | 2019-07-30 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US10385110B2 (en) | 2016-04-21 | 2019-08-20 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US10385111B2 (en) | 2016-04-21 | 2019-08-20 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US10435454B2 (en) | 2016-04-21 | 2019-10-08 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US10035838B2 (en) | 2016-04-21 | 2018-07-31 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US10464991B2 (en) | 2016-04-21 | 2019-11-05 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US9901629B2 (en) | 2016-04-21 | 2018-02-27 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US10640547B2 (en) | 2016-04-21 | 2020-05-05 | Immatics Biotechnologies Gmbh | Immunotherapy against melanoma and other cancers |
US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
CN110064045A (zh) * | 2019-05-15 | 2019-07-30 | 苏州大学 | 微肽cip2a-bp在治疗癌症中的应用 |
CN110064045B (zh) * | 2019-05-15 | 2022-12-23 | 苏州大学 | 微肽cip2a-bp在治疗癌症中的应用 |
AU2021244056B2 (en) * | 2020-03-27 | 2024-04-04 | Onecuregen Co., Ltd. | Composition comprising VGLL1 peptide for treatment of cancer |
WO2024165674A1 (fr) * | 2023-02-08 | 2024-08-15 | Guard Therapeutics International AB | Fragments peptidiques dérivés de alpha-1-microglobuline et leurs utilisations |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7413875B2 (en) | ESTs and encoded human proteins | |
US7235381B2 (en) | Expressed sequence tags and encoded human proteins | |
US6936692B2 (en) | Complementary DNAs | |
EP1033401A2 (fr) | Marqueurs de séquence exprimées et protéines humaines codées | |
EP1037977B1 (fr) | ADNc PROLONGES POUR PROTEINES SECRETEES | |
US20060223142A1 (en) | Extended cDNAs for secreted proteins | |
US7393663B2 (en) | Expressed sequence tags and encoded human proteins | |
US7056680B2 (en) | Antibodies to claudin-50 polypeptide | |
EP1144444A2 (fr) | Adn complementaires codant pour des proteines secretees avec des peptides signaux | |
WO1999006439A2 (fr) | Est 5' pour proteines secretees exprimees dans l'endoderme | |
CA2343602A1 (fr) | Est et proteines humaines codees | |
EP1541683A1 (fr) | ESTs et leurs protéines codées humaines | |
AU2002301051B9 (en) | Extended cDNAs for secreted proteins | |
AU2003262114B2 (en) | cDNAs encoding secreted proteins | |
AU2003204659B2 (en) | Extended cDNAs for secreted proteins | |
EP1903111A2 (fr) | ADN étendus pour protéines secrétées | |
AU1049199A (en) | Extended cdnas for secreted proteins | |
AU2003262217A1 (en) | 5' ESTs and encoded human proteins | |
AU2006225329A1 (en) | cDNAs encoding secreted proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |